AstraZeneca AB filed the patent infringement lawsuit against Sun Pharmaceutical Industries Limited and Sun Pharmaceutical Industries Inc. in November 2023, though the specific drug or patent at issue was not detailed in the dismissal order. The case appears to have been part of the ongoing wave of Hatch-Waxman Act litigation between brand-name drugmakers and generic manufacturers.
The parties reached a settlement agreement that led to the voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). Judge Andrews signed off on the stipulated dismissal order, which specified that all claims and defenses between the parties were dismissed without prejudice, meaning AstraZeneca could potentially refile the lawsuit in the future.
The case was filed in the District of Delaware, a popular venue for patent litigation due to its experienced judges and streamlined procedures. Delaware federal court has become a hub for pharmaceutical patent disputes, particularly those involving generic drug approvals under the Hatch-Waxman Act framework.
The without-prejudice dismissal suggests the parties may have reached a confidential settlement agreement, which is common in pharmaceutical patent litigation. Such agreements often involve licensing deals or delayed generic entry dates that allow both parties to avoid the costs and uncertainty of trial.